Real-World Aflibercept Data Support Extended Time Between Injections
January 14, 2026 • Retinal Diseases Content Hub
Diana Do, MD, professor of ophthalmology and vice chair for clinical affairs, Byers Eye Institute, Stanford University, discusses real-world data presented at the American Academy of Ophthalmology showing that high-dose aflibercept (8 mg) for neovascular age-related macular degeneration and diabetic macular edema may significantly extend the time between injections, up to 12 weeks, while also improving vision. This suggests the higher dose may reduce treatment burden for patients and improve quality of life.
